Alterity Historical Cash Flow

ATHE Stock  USD 1.09  0.03  2.83%   
Analysis of Alterity Therapeutics cash flow over time is an excellent tool to project Alterity Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 17.8 M or Depreciation of 196.8 K as it is a great indicator of Alterity Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Alterity Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Alterity Therapeutics is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.

About Alterity Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Alterity balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Alterity's non-liquid assets can be easily converted into cash.

Alterity Therapeutics Cash Flow Chart

At present, Alterity Therapeutics' Begin Period Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 196.8 K, whereas Free Cash Flow is forecasted to decline to (13.2 M).

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Depreciation

Depreciation indicates how much of Alterity Therapeutics value has been used up. For tax purposes Alterity Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Alterity Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.
Most accounts from Alterity Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Alterity Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.At present, Alterity Therapeutics' Begin Period Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 196.8 K, whereas Free Cash Flow is forecasted to decline to (13.2 M).

Alterity Therapeutics cash flow statement Correlations

-0.17-0.28-0.47-0.120.410.07-0.180.49-0.36-0.390.60.12-0.040.14-0.10.340.7
-0.170.31-0.170.340.440.450.74-0.35-0.460.36-0.59-0.690.010.77-0.350.08-0.12
-0.280.310.040.140.46-0.07-0.31-0.190.420.93-0.290.09-0.04-0.160.06-0.34-0.29
-0.47-0.170.04-0.34-0.08-0.060.050.530.070.15-0.16-0.26-0.3-0.130.10.05-0.31
-0.120.340.14-0.340.110.490.19-0.45-0.180.1-0.130.060.150.06-0.23-0.14-0.04
0.410.440.46-0.080.110.320.040.32-0.360.41-0.04-0.28-0.230.42-0.130.250.13
0.070.45-0.07-0.060.490.320.390.0-0.7-0.10.15-0.22-0.590.32-0.280.620.08
-0.180.74-0.310.050.190.040.39-0.16-0.63-0.16-0.54-0.730.10.84-0.480.18-0.11
0.49-0.35-0.190.53-0.450.320.0-0.16-0.24-0.190.43-0.11-0.34-0.020.010.350.37
-0.36-0.460.420.07-0.18-0.36-0.7-0.63-0.240.330.030.410.45-0.680.37-0.76-0.32
-0.390.360.930.150.10.41-0.1-0.16-0.190.33-0.480.07-0.08-0.030.06-0.33-0.34
0.6-0.59-0.29-0.16-0.13-0.040.15-0.540.430.03-0.480.4-0.27-0.520.250.30.55
0.12-0.690.09-0.260.06-0.28-0.22-0.73-0.110.410.070.4-0.1-0.70.13-0.130.01
-0.040.01-0.04-0.30.15-0.23-0.590.1-0.340.45-0.08-0.27-0.10.05-0.07-0.69-0.06
0.140.77-0.16-0.130.060.420.320.84-0.02-0.68-0.03-0.52-0.70.05-0.490.21-0.06
-0.1-0.350.060.1-0.23-0.13-0.28-0.480.010.370.060.250.13-0.07-0.490.050.37
0.340.08-0.340.05-0.140.250.620.180.35-0.76-0.330.3-0.13-0.690.210.050.43
0.7-0.12-0.29-0.31-0.040.130.08-0.110.37-0.32-0.340.550.01-0.06-0.060.370.43
Click cells to compare fundamentals

Alterity Therapeutics Account Relationship Matchups

Alterity Therapeutics cash flow statement Accounts

201920202021202220232024 (projected)
Change In Cash(5.2M)18.9M6.7M(19.0M)(3.1M)(3.0M)
Free Cash Flow(9.4M)(17.3M)(12.4M)(20.0M)(12.6M)(13.2M)
Change In Working Capital791.1K(4.2M)(447.7K)(3.9M)5.7M6.0M
Begin Period Cash Flow14.4M9.2M28.1M34.8M15.8M17.8M
Other Cashflows From Financing Activities(292.8K)(2.5M)(837.0K)(192.3K)(918.0K)(872.1K)
Depreciation112.4K75.4K54.2K102.3K147.5K196.8K
Other Non Cash Items(12.0K)(2.1M)455.6K(6.3M)(261.2K)(248.1K)
Capital Expenditures16.7K10.5K89.1K7.3K5.7K5.4K
Total Cash From Operating Activities(9.4M)(17.3M)(12.3M)(20.0M)(12.6M)(13.2M)
Net Income(10.1M)(15.3M)(12.8M)(13.8M)(19.1M)(18.2M)
Total Cash From Financing Activities4.0M36.7M16.3M124.3K9.2M10.2M
End Period Cash Flow9.2M28.1M34.8M15.8M12.6M17.9M
Change To Account Receivables3.3M(4.2M)(447.7K)(3.9M)4.6M4.9M
Stock Based Compensation(12.0K)1.9M1.5M966.6K882.0K758.8K
Investments(16.7K)(3K)(89K)(5K)(5.7K)(6.0K)
Total Cashflows From Investing Activities(16.7K)(10.5K)(89.1K)(36.5K)(41.9K)(44.0K)
Change To Operating Activities68.6K(624.0K)(393.3K)(889.5K)(800.6K)(760.5K)
Change To Netincome(275.0K)2.3M(1.3M)59.2K68.0K71.4K
Change To Liabilities(648.6K)432.9K2.6M(1.6M)(1.8M)(1.7M)
Issuance Of Capital Stock4.4M39.2M17.2M311K10.1M11.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.91)
Revenue Per Share
0.6
Quarterly Revenue Growth
0.384
Return On Assets
(0.53)
Return On Equity
(1.04)
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.